Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is having an incredible time in the pre-market hours this morning, and for good reason. The company provided a clinical update, exciting investors and causing the stock to make a run for the top. As is nearly always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (9:33), AUPH is trading at $7.33 per share after a gain of $0.33 per share or 4.71% thus far today.
AUPH Provides Clinical Update
As mentioned above, Aurinia Pharmaceuticals is having a strong day in the market today after providing a clinical update. The company provided additional 48-week results from its global Phase Iib AURA-LV (AURA) study in lupus nephritis. All primary and secondary endpoints were met at the 48 week mark. In a statement, Dr. Samir Parikh, clinical investigator in the AUPH study and Assistant Professor of Clinical Nephrology at the Ohio State University, had the following to offer…
“The most exciting aspect of this data is that voclosporin is the first treatment candidate to successfully meet all of its clinical endpoints in a global, prospective LN trial… Voclosporin, when added to standard of care, achieved the highest complete remission rate of any global, active LN trial, and this was accomplished with extremely low-dose steroid exposure. The possibility of achieving a better clinical response while avoiding the significant side effects associated with prolonged exposure to high dose steroids has the potential to be a game-changer in the management of LN.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on AUPH. In particular, we’re interested in following the company’s work in the treatment of Lupus Nephritis considering the overwhelmingly positive results that we’re seeing. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Want The News Faster?
Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!